Condition: Squamous Cell Anal Carcinoma · Metastatic Squamous Cell Carcinoma · Sponsor: Centre Hospitalier Universitaire de Besancon
This study evaluates the feasibility of the combination of radiotherapy, chemotherapies (docetaxel, cisplatin and 5-fluorouracil) and spartalizumab (anti-PD-1 therapy) in patients with metastatic squamous cell anal carcinoma
This description comes directly from the study's public registry record.
Stefano KIM, Pr · +33 (0)3 81 47 99 99 · stefanokim@gmail.com
Christophe BORG, Pr · +33 (0)3 81 47 99 99 · christophe.borg@efs.sante.fr
Always discuss trial participation with your own doctor first.
| Centre Hospitalier Universitaire de Besançon | Besançon, France | Recruiting |
| Centre Georges-François Leclerc (CGFL) | Dijon, France | Recruiting |
| Hôpital Franco-Britannique | Levallois-Perret, France | Withdrawn |
| Centre Léon Bérard | Lyon, France | Withdrawn |
| Hôpital Nord Franche Comté | Montbéliard, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04894370